Biopharma merger and acquisition value for the fourth quarter of 2022 reached $35.7bn from 41 transactions, 21 of which had disclosed values. Making up 78% of the Q4 total wasAmgen, Inc.’s proposed $27.8bn acquisition of Horizon Therapeutics plc. This deal and three other M&A transactions were the only ones to hit or exceed the billion-dollar mark during Q4 (see Exhibit 1), but nine other deals during this period were valued at $100m or more.
The Amgen/Horizon deal – which marked the largest M&A of the quarter and also for the biopharma industry overall in...